Company profile
Tarsus Pharmaceuticals, Inc.
NASDAQ: TARS · Healthcare · Biotechnology
#220 of 1,422 Healthcare companies by revenuetop-quartile growth
EA Score
62CFH 67DQ 52GM 65SS 65
v0.1 · 65/100 weight · provisional
↑ 3-yr revenue growth, market scale · ↓ growth stability, listing tenure
Methodology →Revenue TTM
$535.1M
Rev growth YoY (TTM)
+129.0%
Net income (FY)
-$66.4M
Employees
370
as of 2026-08-08
Market cap
$2.8B
as of 2026-08-08
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$451.4M$451.4M2025
Net income-$66.4M-$66.4M2025
Operating income-$71.0M-$71.0M2025
Total assets$562.2M$562.2M2025
Liabilities$218.7M$218.7M2025
Equity$343.4M$343.4M2025
Revenue trend
FY2021 – FY2025 · USD
FY21
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Product100%
By geography
Not disclosed.
The read
What is Tarsus Pharmaceuticals, Inc.’s revenue?
Tarsus Pharmaceuticals, Inc. booked $451.4M in FY2025 revenue, growing 147% year over year — faster than most Healthcare companies we track, at a -14.7% net margin.
Peers · Healthcare
Phreesia, Inc.68BAyr Wellness Inc.——Accuray Incorporated68BArtivion, Inc.80B+Atlantic International Corp.39DGeneDx Holdings Corp.64CNeighbors
Orange →Key facts
CEOBobak R. Azamian
SectorHealthcare
IndustryBiotechnology
HeadquartersIrvine, CA
ExchangeNASDAQ: TARS
Employees370
IPO date2020-10-16
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.